Feasibility of Intermittent Fasting During Chemotherapy

Launched by UNIVERSITY OF OSLO · Oct 15, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring whether intermittent fasting—meaning not eating for certain periods before and after chemotherapy—is safe and acceptable for patients with Hodgkin lymphoma or Diffuse Large B Cell Lymphoma. The researchers want to see if fasting can be included in cancer treatment, how it affects patients’ health and quality of life, and whether it leads to any side effects. Participants will either fast for 24 hours before and after their chemotherapy sessions or receive standard treatment without fasting. They will also keep track of what they eat and report any side effects they experience.

To participate, individuals need to be at least 18 years old and diagnosed with specific types of lymphoma. They should have a normal or slightly overweight body mass index (BMI) and be in good health overall. However, those with certain health conditions, like diabetes or severe weight issues, won't be eligible. Participants can expect to keep food diaries, answer questions about their experiences, and provide some health measurements and samples during the study. This trial will help determine if fasting could be a beneficial addition to cancer treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients diagnosed with diffuse large B-cell lymphoma planned to receive R-CHOP (rituximab, vincristine, doxorubicin, cyclophosphamide, and prednisolone) and Hodgkin lymphoma receiving ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine)
• • Age ≥ 18 years
• • ECOG status 0-2
• • Normal weight and overweight (BMI ≥ 18,5 kg/m\^2)
• Exclusion Criteria:
• • Receiving concurrent radiation therapy and/or treatment
• • Other concomitant disease that may make intermittent fasting complicated such as diabetes mellitus
• • ECOG status: \> 3
• • BMI \< 18,5 kg/m2
• • Age \> 80 years